[EN] MLL1 INHIBITORS AND ANTI-CANCER AGENTS<br/>[FR] INHIBITEURS DE MLL1 ET AGENTS ANTICANCÉREUX
申请人:NOVARTIS AG
公开号:WO2021239077A1
公开(公告)日:2021-12-02
The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL1).
本发明提供了一种公式(I)的化合物:或其对映体、对映体混合物或药学上可接受的盐;其中变量如本文所定义。本发明还提供了包含这样的化合物的药物组合物;以及使用这样的化合物治疗由混合谱系白血病1(MLL1)介导的疾病或病况的方法。